The FDA has approved Medtronic’s iPro2, a next-generation professional continuous glucose monitoring system (CGMS). The new 6-day evaluation system is designed to make continuous glucose monitoring easy for health care professionals and patients to use. It can be used to identify nocturnal hypoglycemia or postprandial hyperglycemia. The setup procedure is a three-step process enabled by a new “smart” dock, which reduces the number of required components and eliminates the need for a computer. The patient performs normal daily activities while the system records and stores as many as 288 glucose readings during each 24-hour period. After 6 days of wear, the patient returns the system for upload to Web-based software, which provides a summary of glucose data. The reports can be used to motivate patients to implement changes in their diabetes management based on the effects that food, exercise, stress, medications or other activities have on glucose levels.